Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortalityrate found throughout the world especially in Southeast Asia and Thailand. Many factors determinethe outcome of the treatment for HCC including the stage of the cancer and liver function. Sorafenibis the current standard treatment for advanced HCC. Many studies have not shown any benefit of usingSorafenib after tumor resection or ablation and the combination of Sorafenib with transarterialchemoembolization. Lenvatinib, Regorafenib and Nivolumab have been studied in Advanced HCCwith preserved liver function with promising results. Surveillance for HCC in high-risk patientsremains the tools to deliver better outcomes for patient with HCC.
 
 Keywords: HCC, advanced stage, therapy, Sorafenib, Lenvatinib, Regorafenib, Nivolumab
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
